29 June 2015
Immunocore and Lilly announce immunotherapy-based clinical trial collaboration in melanoma
(Oxford, UK, and Indianapolis, 29 June 2015) Immunocore Limited and Eli Lilly and Company (NYSE: LLY) today announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. The goal of the collaboration is to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas.
Under the terms of the agreement, Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted combining IMCgp100 with merestinib in metastatic uveal melanoma. Lilly will act as trial sponsor. These studies are anticipated to begin in 2016. No financial terms were disclosed.
Please click on the link below to download the full Press Release: